Naringenin ameliorates pathological changes in liver and kidney of diabetic mice: a preliminary study / Naringenin reducira histopatološke promjene u jetri i bubregu miševa s dijabetesom

Sirovina, Damir; Oršolić, Nada; Gregorović, Gordana; Končić, Marijana Zovko

doi:10.1515/aiht-2016-67-2708

Cited by 33 publications

(20 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a type of flavonoid, Nar is the predominant flavanone in grapefruit and is found to have strong anti-inflammatory, antioxidant, and organ-protective activities. A previous study has indicated that Nar alleviates the histopathological changes in the liver and kidney caused by alloxan-induced diabetes in mice [ 20 ]. Nar can downregulate TNF-a, IL-1 β , IL-6, IL-10, and other inflammatory cytokines in macrophages infected with live Chlamydia trachomatis [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

Naringenin Protects against Acute Pancreatitis in Two Experimental Models in Mice by NLRP3 and Nrf2/HO-1 Pathways

Pan

Gao

et al. 2018

Mediators of Inflammation

View full text Add to dashboard Cite

Background Naringenin (Nar) is a type of flavonoid and has been shown to have anti-inflammatory and antioxidative properties. However, the effects of Nar on acute pancreatitis (AP) have not been well studied. In this study, we aimed to investigate the function of Nar in a mouse model of AP. Methods Mild acute pancreatitis (MAP) was induced by caerulein (Cae), and severe acute pancreatitis (SAP) was induced by L-arginine in mice. Nar was administered intraperitoneally at doses of 25, 50, or 100 mg/kg following MAP induction and at a dose of 100 mg/kg following SAP induction. The serum levels of cytokines, lipase, and amylase were determined, and pancreatic and pulmonary tissues were harvested. Results The serum levels of amylase, lipase, and cytokines were significantly decreased in both MAP and SAP models after Nar treatment. The malondialdehyde (MDA) levels of the pancreatic tissue was significantly reduced in both MAP and SAP after Nar treatment. In contrast, glutathione peroxidase (GPx), glutathione reductase (GR), glutathione S-transferase (GST), total sulfhydryl (T-SH), and non-proteinsulthydryl (NP-SH) were markedly increased in both MAP and SAP after Nar treatment. The injury in pancreatic and pulmonary tissues was markedly improved as evidenced by the inhibited expression of myeloperoxidase, nod-like receptor protein 3, and interleukin 1 beta as well as the enhanced expression of nuclear factor erythroid 2-related factor 2/heme oxygenase-1 in pancreatic tissues. Conclusions Nar exerted protective effects on Cae-induced MAP and L-arginine-induced SAP in mice, suggesting that Nar may be a potential therapeutic intervention for AP.

show abstract

Section: Discussionmentioning

confidence: 99%

Naringenin Protects against Acute Pancreatitis in Two Experimental Models in Mice by NLRP3 and Nrf2/HO-1 Pathways

Pan

Gao

et al. 2018

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…It has been reported that, in diabetic rats, naringenin reduced diabetic markers through PPARγ and glucose transporter Type 4 (GLUT4) and increased their gene and protein expression levels in pancreas [36]. In the liver, naringenin increased glycogen content, decreased activities of glycogen phosphorylase and glucose-6-phosphatase [37] and ameliorated diabetes induced hepatotoxicity [38]. In the extracts from M. charantia, compounds like rutin and daidzein and naringenin are the most common, but epicatechin (-) is the one with the highest concentration (143.34 mg/kg).…”

Section: Discussionmentioning

confidence: 99%

Exploring Antioxidant and Enzymes (A-Amylase and B-Glucosidase) Inhibitory Activity of Morinda lucida and Momordica charantia Leaves from Benin

Chokki

Cudalbeanu

Zongo

et al. 2020

Foods

View full text Add to dashboard Cite

Background: Momordica charantia Linn. (Cucurbitaceae), the wild variety of bitter melon and Morinda lucida Benth (Rubiaceae) were commonly used as a popular folk medicine in Benin. This research focused to measure the antioxidant and enzyme inhibitory effects of M. charantia and M. lucida leaves and their antidiabetic activity. Methods: Antioxidant activities were evaluated by micro-dilution technique using DPPH free radical scavenging activity and β-carotene-linoleate bleaching assay. The α-amylase inhibition assay was carried out utilizing the 3,5-dinitrosalicylic acid procedure, while β-glucosidase inhibition assay was demonstrated using as substrate p-nitrophenyl-β-D-glucopyranoside (PNPG). HPLC-DAD analysis was realized using a high-performance liquid chromatography systems with diode-array detector, L-3000. Results: Chlorogenic acid, epicatechin, daidzein, rutin, naringin, quercetin, naringenin and genistein were identified as polyphenol compounds in the both plants extract. Dichloromethane and ethyl acetate extracts showed a good α-amylase inhibitory activity (56.46 ± 1.96% and 58.76 ± 2.74% respectively). M. lucida methanolic extract has shown IC50 of 0.51 ± 0.01 mg/mL, which is the lowest for DPPH scavenging activity. M. lucida dichloromethane extract showed the highest inhibitory capacity of β-glucosidase activity (82.11. ± 2.15%). Conclusion: These results justify some traditional medicinal uses of both plants. The purified fractions could be used in future formulations, possibly incorporated in functional foods to combat certain diseases.

show abstract

“…It has been reported that, in diabetic rats, the flavonoid reduced diabetic markers through PPARγ and glucose transporter type 4 (GLUT4) and increased their gene and protein expression levels in pancreas[ 210 ]. In the liver, naringenin increased glycogen content, decrease activities of glycogen phosphorylase and glucose-6- phosphatase[ 211 ] and ameliorated diabetes-induced hepatotoxicity[ 212 , 213 ]. For more information see Nyane et al[ 214 ].…”

Section: Antidiabetic Effect Of Naringeninmentioning

confidence: 99%

Beneficial effects of naringenin in liver diseases: Molecular mechanisms

Hernández-Aquino

Muriel

2018

WJG

270

176

View full text Add to dashboard Cite

Liver diseases are caused by different etiological agents, mainly alcohol consumption, viruses, drug intoxication or malnutrition. Frequently, liver diseases are initiated by oxidative stress and inflammation that lead to the excessive production of extracellular matrix (ECM), followed by a progression to fibrosis, cirrhosis and hepatocellular carcinoma (HCC). It has been reported that some natural products display hepatoprotective properties. Naringenin is a flavonoid with antioxidant, antifibrogenic, anti-inflammatory and anticancer properties that is capable of preventing liver damage caused by different agents. The main protective effects of naringenin in liver diseases are the inhibition of oxidative stress, transforming growth factor (TGF-β) pathway and the prevention of the transdifferentiation of hepatic stellate cells (HSC), leading to decreased collagen synthesis. Other effects include the inhibition of the mitogen activated protein kinase (MAPK), toll-like receptor (TLR) and TGF-β non-canonical pathways, the inhibition of which further results in a strong reduction in ECM synthesis and deposition. In addition, naringenin has shown beneficial effects on nonalcoholic fatty liver disease (NAFLD) through the regulation of lipid metabolism, modulating the synthesis and oxidation of lipids and cholesterol. Moreover, naringenin protects from HCC, since it inhibits growth factors such as TGF-β and vascular endothelial growth factor (VEGF), inducing apoptosis and regulating MAPK pathways. Naringenin is safe and acts by targeting multiple proteins. However, it possesses low bioavailability and high intestinal metabolism. In this regard, formulations, such as nanoparticles or liposomes, have been developed to improve naringenin bioavailability. We conclude that naringenin should be considered in the future as an important candidate in the treatment of different liver diseases.

show abstract

Naringenin ameliorates pathological changes in liver and kidney of diabetic mice: a preliminary study / Naringenin reducira histopatološke promjene u jetri i bubregu miševa s dijabetesom

Cited by 33 publications

References 32 publications

Naringenin Protects against Acute Pancreatitis in Two Experimental Models in Mice by NLRP3 and Nrf2/HO-1 Pathways

Naringenin Protects against Acute Pancreatitis in Two Experimental Models in Mice by NLRP3 and Nrf2/HO-1 Pathways

Exploring Antioxidant and Enzymes (A-Amylase and B-Glucosidase) Inhibitory Activity of Morinda lucida and Momordica charantia Leaves from Benin

Beneficial effects of naringenin in liver diseases: Molecular mechanisms

Contact Info

Product

Resources

About